Enhanced resection and improved survival in murine neuroblastoma (C1300-NB) after preoperative immunotherapy.

Abstract

Advanced neuroblastoma treated with standard chemotherapy has a poor prognosis. Combination immunotherapy for murine neuroblastoma with retinyl palmitate, low-dose cyclophosphamide, and interleukin-2 resulted in increased survival, impaired tumor growth, easier surgical resection, and increased class I expression or tumor cells. Preoperative immunotherapy may be useful in treatment of advanced human neuroblastoma.

• Authors: C L Fowler, S P Brooks, R Squire, G A Rich, J E Rossman, M J Finegold, J E Allen, D R Cooney
• Journal: Journal of pediatric surgery (J Pediatr Surg) Vol. 26 Issue 4 Pg. 381-7; discussion 387-8 (Apr 1991) ISSN: 0022-3468 [Print] United States
• PMID: 2056397 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Diterpenes
• Histocompatibility Antigens Class I
• Interleukin-2
• Recombinant Proteins
• Retinyl Esters
• Vitamin A
• retinol palmitate
• Cyclophosphamide

Topics

• Animals
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Combined Modality Therapy
• Cyclophosphamide (administration & dosage)
• Diterpenes
• Female
• Histocompatibility Antigens Class I (biosynthesis)
• Immunotherapy
• Interleukin-2 (administration & dosage)
• Mice
• Mice, Inbred A
• Neuroblastoma (immunology, pathology, surgery, therapy)
• Preoperative Care
• Recombinant Proteins (administration & dosage)
• Retinyl Esters
• Survival Rate
• Vitamin A (administration & dosage, analogs & derivatives)